Table 6.
Sensitivity analysis exploring the influence of the degree of Influenza B lineage cross protection L
| L |
Influenza B |
Prevented infections |
|||
|---|---|---|---|---|---|
| No vaccination | TIV | QIV | QIV-TIV | % | |
| 0% |
8283 |
6552 |
4372 |
2180 |
17,9 |
| (8224–8394) |
(6477–6627) |
(4313–4431) |
(2142–2217) |
(17,6-18,2) |
|
| 10% |
7557 |
5760 |
4009 |
1751 |
15,4 |
| (7491–7649) |
(5692–5827) |
(3954–4063) |
(1716–1786) |
(15,1-15,7) |
|
| 20% |
6961 |
5140 |
3772 |
1368 |
12,7 |
| (6890–7037) |
(5079–5200) |
(3720–3824) |
(1336–1399) |
(12,5-13,0) |
|
| 30% |
6491 |
4624 |
3574 |
1050 |
10,2 |
| (6445–6587) |
(4569–4680) |
(3526–3623) |
(1020–1080) |
(10,0-10,5) |
|
| 40% |
6144 |
4216 |
3386 |
830 |
8,4 |
| (6070–6206) |
(4163–4269) |
(3339–3433) |
(801–859) |
(8,1-8,7) |
|
| 50% |
5837 |
3865 |
3276 |
589 |
6,2 |
| (5783–5916) |
(3815–3914) |
(3230–3322) |
(562–615) |
(5,9-6,5) |
|
| 60% |
5229 |
3346 |
2951 |
395 |
4.3 |
| (5183–5275) | (3313–3379) | (2920–2982) | (376–414) | (4.1-4.5) | |
Average annual results (with 95% confidence intervals) obtained for the 20 year evaluation period (calculated from 1,000 simulations for each combination of L and vaccination strategy in a simulated population of about 80,000 individuals (2,000 simulations each for the baseline parameter value L = 60%; boldface line). The last column shows what percentage of all influenza A and B infections which occur under TIV vaccination can additionally be prevented by QIV.